Income taxes	9 Months Ended
Sep. 30, 2019
Income taxes	NOTE 19 – Income taxes: In the third quarter of 2019, Teva recognized a tax expense of $ 11 million , on pre-tax loss of $ 292 million . In the third quarter of 2018, Teva recognized a tax benefit of $ 26 million , or 12%, on pre-tax loss of $ 213 million . Teva’s tax rate for the third quarter of 2019 was mainly affected by impairments, amortization , legal settlements with low corresponding tax effect and interest disallowance as a result of the U.S. Tax Cuts and Jobs Act. In the first nine months of 2019, Teva recognized a tax benefit of $ 159 million , or 13%, on pre-tax loss of $ 1,226 million . In the first nine months of 2018, Teva recognized a tax benefit of $ 56 million on pre-tax income of $ 791 million . Teva’s tax rate for the first nine months of 2019 was mainly affected by impairments, amortization , legal settlements with low corresponding tax effect and interest disallowance as a result of the U.S. Tax Cuts and Jobs Act. The statutory Israeli corporate tax rate is 23 % in 2019. Teva’s tax rate differs from the Israeli statutory tax rate, mainly due to generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate, tax benefits in Israel and other countries, as well as infrequent or nonrecurring items. Teva filed a claim seeking the refund of withholding taxes paid to the Indian tax authorities in 2012. Trial in this case is scheduled to begin in November 2019. A final and binding decision against Teva in this case may lead to an impairment in the amount of $146 million.

Income taxes

9 Months Ended

Sep. 30, 2019

NOTE 19 – Income taxes:

In the third quarter of 2019, Teva recognized a tax

expense

million

pre-tax

loss

292

million

. In the third quarter of 2018, Teva recognized a tax benefit of

million

, or 12%, on

pre-tax

loss of

213

million

. Teva’s tax rate for the third quarter of 2019 was mainly affected by impairments, amortization

, legal settlements with low corresponding tax effect

and interest disallowance as a result of the U.S. Tax Cuts and Jobs Act.

In the first

nine

months of 2019, Teva recognized a tax benefit of

159

million

, or 13%, on

pre-tax

loss of

1,226

million

. In the first

nine

months of 2018, Teva recognized a tax benefit of

million

pre-tax

income of

791

million

. Teva’s tax rate for the first

nine

months of 2019 was mainly affected by impairments, amortization

, legal settlements with low corresponding tax effect

and interest disallowance as a result of the U.S. Tax Cuts and Jobs Act.

The statutory Israeli corporate tax rate is 23

in 2019.

Teva’s tax rate differs from the Israeli statutory tax rate, mainly due to generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate, tax benefits in Israel and other countries, as well as infrequent or nonrecurring items.

Teva filed a claim seeking the refund of withholding taxes paid to the Indian tax authorities in 2012. Trial in this case is scheduled to begin in November 2019. A final and binding decision against Teva in this case may lead to an impairment in the amount of $146 million.